GCC Healthcare Market Projections: Opportunities from 2024 to 2030
GCC Healthcare Innovation Market
Dublin, Aug. 18, 2025 (GLOBE NEWSWIRE) -- The "Healthcare Innovation in the GCC" report has been added to ResearchAndMarkets.com's offering.The report provides an analysis of the healthcare landscape in the Gulf Cooperation Council (GCC) countries. The report estimates the Total Addressable Market (TAM) for the GCC healthcare sector from 2024 to 2030, offering country-specific projections.
This analysis provides critical insights into the commercial potential and investment opportunities in the region's rapidly evolving healthcare ecosystem. The countries included in the analysis are Saudi Arabia, the United Arab Emirates (UAE), Qatar, Kuwait, Oman, and Bahrain.
A key focus of the report is the evaluation of government policies aimed at strengthening the healthcare sector. This includes assessing each country's commitment to enhancing healthcare infrastructure, expanding the healthcare workforce, and increasing public and private healthcare spending.
The analysis highlights how national strategies such as Vision 2030 are driving systemic transformation within the sector. The report incorporates the latest available data, including figures on the number of hospitals, hospital beds, and specialized medical staff, with most datasets available up to 2023.The study further examines the scale and diversity of healthcare infrastructure in the region, covering the number of hospitals, the development of specialized facilities, and the emergence of local biotech and pharmaceutical companies. It also highlights investment-friendly regulations and policy reforms that are fostering a favorable business environment for domestic and foreign stakeholders.Key emerging trends are explored, including the growing adoption of artificial intelligence (AI), digital health platforms, electronic medical records, telemedicine, and other smart healthcare technologies. These innovations are pivotal in improving service delivery, patient outcomes, and system efficiency.The analysis provides critical insights into the commercial potential and investment opportunities in the region's rapidly evolving healthcare ecosystem.This study is intended to serve as a strategic resource for policymakers, investors, healthcare providers, technology firms, and research institutions. It will equip these groups with a detailed framework to understand the sector's growth trajectory, partnership potential, and innovation landscape.The report includes:
An analysis of innovation in healthcare technologies in the GCC (Gulf Cooperation Council) countries
Analyses of the GCC market trends, with revenue data for 2024, estimates for 2025, and projected CAGRs through 2030
Estimates of the size and revenue prospects of the GCC healthcare market, and a corresponding share analysis by sector (care settings), application and emerging countries
Facts and figures pertaining to the current market dynamics, technological advances, regulations and the impact of macroeconomic factors
Analysis of the industry structure, including companies' product offerings, strategic alliances, venture fundings and investment outlook
Key Attributes:
Report Attribute
Details
No. of Pages
56
Forecast Period
2025 - 2030
Estimated Market Value (USD) in 2025
$121.9 Billion
Forecasted Market Value (USD) by 2030
$170.5 Billion
Compound Annual Growth Rate
5.9%
Regions Covered
Middle East
Key Topics Covered: Chapter 1 Executive Summary
Market Outlook
Scope of Report
Reasons for Doing this Study
Market Summary
Chapter 2 GCC Healthcare Industry Outlook
SWOT Analysis of the GCC Healthcare Industry
Pestle Analysis of GCC Healthcare Industry
Chapter 3 Market Dynamics
Market Drivers
High Prevalence of Non-Communicable Diseases
Growing Investments and Funding in the GCC Region
Economic Growth in the GCC Region
Market Restrains
Higher Dependence on Imports of Healthcare Products
Shortage of Healthcare Professionals
Market Opportunities
Increasing Focus on Medical Tourism in the GCC
Expansion of AI and Digital Healthcare Solutions
Chapter 4 Saudi Arabia Healthcare Industry Outlook
Market Size Analysis
Healthcare Expenditure Overview
Country Healthcare Infrastructure Overview
Healthcare Innovation Overview
Chapter 5 United Arab Emirates (UAE) Healthcare Industry Outlook
Chapter 6 Kuwait Healthcare Industry Outlook
Chapter 7 Oman Healthcare Industry Outlook
Chapter 8 Qatar Healthcare Industry Outlook
Chapter 9 Bahrain Healthcare Industry Outlook
Chapter 10 Concluding Remarks and Recommendations
Recommendations for Strengthening Healthcare Innovation and Collaboration in the GCC
For more information about this report visit https://www.researchandmarkets.com/r/60tnhk
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
GCC Healthcare Innovation Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900擷取數據時發生錯誤
登入存取你的投資組合
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Medical Transportation Firm Modivcare Files for Bankruptcy
Medical transportation firm Modivcare Inc. filed for bankruptcy in an effort to shed $1.1 billion of debt, after federal health-care funding cuts complicated the company's future finances. The company filed for Chapter 11 in the US Bankruptcy Court for the Southern District of Texas on Wednesday, according to a statement. Bloomberg previously reported that Modivcare was weighing a Chapter 11 filing.
Yahoo
an hour ago
- Yahoo
3 Asian Penny Stocks With Market Caps Under US$400M
As global markets react to economic data and potential interest rate changes, Asian markets have shown resilience, with key indices like Japan's Nikkei 225 reaching record highs. Amidst this backdrop, the concept of penny stocks—often seen as a relic from past market eras—remains relevant due to their potential for growth at lower price points. These stocks typically represent smaller or newer companies that can offer significant opportunities when backed by strong financials and sound fundamentals. Top 10 Penny Stocks In Asia Name Share Price Market Cap Financial Health Rating Food Moments (SET:FM) THB4.00 THB3.95B ★★★★★☆ JBM (Healthcare) (SEHK:2161) HK$3.07 HK$2.5B ★★★★★★ Lever Style (SEHK:1346) HK$1.63 HK$1.01B ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.65 HK$2.21B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.625 SGD253.31M ★★★★★☆ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.83 SGD11.14B ★★★★★☆ Ekarat Engineering (SET:AKR) THB0.95 THB1.4B ★★★★★★ Livestock Improvement (NZSE:LIC) NZ$0.95 NZ$135.23M ★★★★★★ Rojana Industrial Park (SET:ROJNA) THB4.64 THB9.37B ★★★★★☆ BRC Asia (SGX:BEC) SGD3.64 SGD998.63M ★★★★★★ Click here to see the full list of 970 stocks from our Asian Penny Stocks screener. Let's explore several standout options from the results in the screener. Hengxin Technology Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Hengxin Technology Ltd. is an investment holding company involved in the research, design, manufacture, development, and sale of integrated antennas and feeder cables for mobile communications both in the People's Republic of China and internationally, with a market cap of HK$1.02 billion. Operations: Hengxin Technology generates revenue from three main segments: Telecommunications Business (CN¥2.10 billion), New Energy and Services Business (CN¥185.97 million), and Integrated Circuits and Digital Technology (CN¥238.35 million). Market Cap: HK$1.02B Hengxin Technology Ltd., with a market cap of HK$1.02 billion, operates across telecommunications, new energy, and integrated circuits sectors. Despite negative earnings growth over the past year and declining profits over five years, the company maintains a satisfactory net debt to equity ratio of 25.8% and covers short-term liabilities with assets of CN¥2.9 billion. Recent strategic expansion into green energy infrastructure through an 800MW/1600MWh storage project in Shandong Province marks a significant milestone for future growth potential. However, frequent board changes may indicate instability; recent appointments include experienced financial professionals to strengthen governance. Click to explore a detailed breakdown of our findings in Hengxin Technology's financial health report. Evaluate Hengxin Technology's historical performance by accessing our past performance report. VPower Group International Holdings Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: VPower Group International Holdings Limited is an investment holding company that designs, integrates, sells, and installs engine-based electricity generation units across Hong Kong, Mainland China, other Asian countries, Latin America, and internationally with a market cap of approximately HK$1.90 billion. Operations: The company's revenue is primarily derived from its System Integration segment, which generated HK$628.55 million, and its Investment, Building and Operating segment, contributing HK$917.56 million. Market Cap: HK$1.9B VPower Group International Holdings, with a market cap of HK$1.90 billion, is navigating financial challenges as it remains unprofitable with losses increasing over the past five years. However, the company has maintained stable weekly volatility and avoided shareholder dilution recently. Its short-term assets exceed both short and long-term liabilities, providing some financial stability despite a high net debt to equity ratio of 127.2%. Recent corporate guidance indicates an expected profit of approximately HK$20 million for H1 2025 due to asset disposals and reduced interest expenses, contrasting with a significant loss in the previous year. Take a closer look at VPower Group International Holdings' potential here in our financial health report. Learn about VPower Group International Holdings' historical performance here. C-MER Medical Holdings Simply Wall St Financial Health Rating: ★★★★★☆ Overview: C-MER Medical Holdings Limited is an investment holding company that offers ophthalmic services under the C-MER Dennis Lam brand in Hong Kong and Mainland China, with a market cap of HK$2.59 billion. Operations: The company generates revenue from its Hong Kong medical business (HK$901.59 million), Mainland China dental operations (HK$464.58 million), and ophthalmic services in Mainland China (HK$546.99 million). Market Cap: HK$2.59B C-MER Medical Holdings, with a market cap of HK$2.59 billion, faces profitability challenges as losses have grown at 16.5% annually over the past five years. Despite this, the company maintains financial stability with short-term assets exceeding liabilities and cash reserves surpassing total debt. Recent strategic moves include a share buyback program aimed at enhancing net asset value per share and earnings per share, signaling confidence in its long-term prospects. Leadership changes see Dr. Lam transitioning to a senior advisor role while Ms. Li Xiaoting assumes CEO duties, potentially ensuring continuity in corporate strategy and operations. Navigate through the intricacies of C-MER Medical Holdings with our comprehensive balance sheet health report here. Review our historical performance report to gain insights into C-MER Medical Holdings' track record. Make It Happen Get an in-depth perspective on all 970 Asian Penny Stocks by using our screener here. Curious About Other Options? AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1085 SEHK:1608 and SEHK:3309. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
an hour ago
- Yahoo
NUTEX HEALTH PROVIDES FINANCIAL REPORTING UPDATE
HOUSTON, Aug. 20, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments in 11 states and primary care-centric, risk-bearing physician networks, today disclosed non-reliance on its (i) unaudited condensed consolidated financial statements as of and for the three months ended March 31, 2025 contained in the Form 10-Q for the period ended March 31, 2025 (the "Original Form 10-Q") and its (ii) audited consolidated financial statements as of and for the years ended December 31, 2024 and 2023 contained in the Form 10-K for the year ended December 31, 2024 and 2023 (the "Original Form 10-K") (collectively, the "Previously Issued Financial Statements"). As noted in the 8-K filed today, on August 20, 2025, the Company, in consultation with the Audit Committee of the Board of Directors and its Auditor, reached a determination that the Company's Previously Issued Financial Statements should no longer be relied upon solely due to changes to the non-cash classification of obligations related to under construction and ramping hospitals from equity to liability in accordance with the classification criteria in ASC 718, Compensation - Stock Compensation, and ASC 480, Distinguishing Liabilities from Equity. For additional clarity, this non-reliance is anticipated to be non-cash adjustments that are not due to issues related to collections or Independent Dispute Resolutions (arbitration) related activities. The Company has determined that it is appropriate to correct the classification in the Company's Previously Issued Financial Statements by amending its Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the "First Quarter 2025 Form 10-Q/A"), and its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the "2024 Form 10-K/A"). The Company expects that any adjustments related to the treatment of these obligations will be non-cash and have no effect on key financial statement line items such as its revenue, gross profit, liquidity, working capital, short-term and long-term debt, operating cash flow, adjusted EBITDA or number of patient visits. Preliminary Financial Information Prior to the filing of the First Quarter 2025 Form 10-Q/A, the 2024 Form 10-K/A, and the full financial results for the period ended June 30, 2025, the Company has provided below select preliminary unaudited financial results for the three and six months ended June 30, 2025, which reflect management's current views with respect to the Company's financial results. These preliminary results remain subject to the completion of normal quarter-end and fiscal-end accounting procedures and closing adjustments. Financial highlights for the three months ended June 30, 2025: Total revenue was $244.0 million for the three months ended June 30, 2025 as compared to total revenue of $76.1 million for the same period in 2024, an increase of 220.7%. Revenue from mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 203.2% in 2025 compared to 2024. Gross profit was $124.8 million, or 51.1% of total revenue, for the three months ended June 30, 2025 as compared to gross profit of $22.6 million, or 29.7% of total revenue, for the same period in 2024. Total visits at the Hospital Division were 45,573 for the three months ended June 30, 2025, as compared to 41,208 for the same period in 2024, an increase of 4,365 or 10.6%. Visits at mature hospitals increased by 0.6% in the three months ended June 30, 2025 as compared to the same period in 2024. For the three months ended June 30, 2025, the Company collected $175 million in cash, the highest collection amount for any quarter. Adjusted EBITDA was $71.6 million for the three months ended June 30, 2025 as compared to $6.8 million for the same period in 2024. Operating cash flow was $27.1 million for the three months ended June 30, 2025 as compared to $13.3 million for the same period in 2024. Financial highlights as of and for the six months ended June 30, 2025: Total revenue was $455.8 million for the six months ended June 30, 2025, as compared to total revenue of $143.5 million for the same period in 2024, an increase of 217.5%. Revenue from mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 195.2% in 2025 compared to 2024. Gross profit was $243.1 million, or 53.3% of total revenue, for the six months ended June 30, 2025, as compared to gross profit of $32.7 million, or 22.8% of total revenue, for the same period in 2024. Total visits at the Hospital Division were 93,842 for the six months ended June 30, 2025, as compared to 81,276 for the same period in 2024, an increase of 12,566 or 15.5%. Visits at mature hospitals increased by 3.0% in the six months ended June 30, 2025, as compared to the same period in 2024. For the six months ended June 30, 2025, the Company collected $311 million in cash, the highest collection amount for the first two quarters of any year. Adjusted EBITDA was $144.4 million for the six months ended June 30, 2025, as compared to $6.4 million for the same period in 2024. Operating cash flow was $78.1 million for the six months ended June 30, 2025, as compared to $16.3 million for the same period in 2024. As of June 30, 2025, the Company had total assets of $854.8 million, including cash of $96.4 million and accounts receivable of $349.2 million. Current portion of long-term debt and long-term debt was $15.0 million and $20.5 million, respectively, as of June 30, 2025. Additional Information The Company will host a shareholder update call to be scheduled for Monday August 25, 2025 at 10:30 am Eastern Time, where it will discuss preliminary second quarter financials as well as other topics relevant to the Company, as also described in its Form 8-K filed on the date hereof. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant Link: To access the call, please dial in approximately five minutes before start time. Those who are unable to attend the live conference call may access the recording on the Company's website. Notification of Delinquency with Nasdaq On August 20, 2025, Nutex received a delinquency notification letter from Nasdaq, which indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the delayed filing of the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2025. While this notice does not immediately affect the listing of Nutex's securities, the company risks delisting if it does not resolve the issue by submitting a compliance plan to Nasdaq by October 20, 2025, 60 days from August 20, 2025. If accepted, Nutex could have until February 10, 2026, to comply. Nutex is currently working to complete its delayed financial filings. About Nutex Health Inc. Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division. The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 24 facilities in 11 states. The Population Health Management division owns and operates provider networks such as Independent Physician Associations. Through our Management Services Organization, we provide management, administrative and other support services to our affiliated hospitals and physician groups. Forward-Looking Statements This Press Release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including, but not limited to, statements regarding future changes in laws or regulations applicable to our operations, in particular, changes to the regulations promulgated under the No Surprises Act, any statements about our business, financial condition, operating results, plans, objectives, expectations and intentions, any guidance on, or projections of, earnings, revenue or other financial items, or otherwise, and our future liquidity, including cash flows; any statements regarding the timing of the filing of the amendments to our prior SEC filings and 10-Q for the second quarter of 2025; any statements of any plans, strategies, and objectives of management for future operations, such as the material opportunities that we believe exist for our Company; any statements concerning proposed services, developments, mergers or acquisitions; or strategic transactions; any statements regarding management's view of future expectations and prospects for us; any statements about prospective adoption of new accounting standards or effects of changes in accounting standards; any statements regarding future economic conditions or performance; any statements of belief; any statements of assumptions underlying any of the foregoing; and other statements that are not historical facts. Forward-looking statements may be identified by the use of forward-looking terms such as "anticipate," "could," "can," "may," "might," "potential," "predict," "should," "estimate," "expect," "project," "believe," "think," "plan," "envision," "intend," "continue," "target," "seek," "contemplate," "budgeted," "will," "would" and the negative of such terms, other variations on such terms or other similar or comparable words, phrases or terminology. Forward-looking statements involve risks and uncertainties and are based on the current beliefs, expectations, and certain assumptions of management. Some or all of such beliefs, expectations, and assumptions may not materialize or may vary significantly from actual results. Such statements are qualified by important economic, competitive, governmental, and technological factors that could cause our business, strategy, or actual results or events to differ materially from those in our forward-looking statements. When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements described under, but not limited to, the heading "Item 1A. Risk Factors" included in the Annual Report of Nutex Health Inc. on Form 10-K for the year ended December 31, 2024 and other filings of the Company with the United States Securities and Exchange Commission. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change, and significant risks and uncertainties that could cause actual conditions, outcomes and results to differ materially from those indicated by such statements. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequence to or effects on the Company or its business or operations. The Company assumes no obligations to update any such forward-looking statements. View original content: SOURCE Nutex Health, Inc. Sign in to access your portfolio
